

1 **Maternal obesity shapes the B lymphocyte and antibody repertoires of**
2 **human colostrum**

3

4 Erick Sánchez-Salguero¹, Diana Bonilla-Ruelas¹, Mario René Alcorta-García^{2,4},
5 Víctor Javier Lara-Díaz^{3,6}, Claudia Nohemí López-Villaseñor^{2,4}, Marion E G
6 Brunck^{1,5*}

7 ¹ The Institute for Obesity Research, Tecnológico de Monterrey, Av. Eugenio Garza Sada
8 2501 Sur, Tecnológico, 64700, Monterrey, Nuevo León, México.

9 ² Hospital Regional Materno Infantil, Servicios de Salud de Nuevo León, OPD, Av. San
10 Rafael 460, San Rafael, 67140 Guadalupe, Nuevo León, México.

11 ³ Pediatras404, San Pedro Garza Garcia, Nuevo León, México.

12 ⁴ School of Medicine and Health Sciences, Tecnológico de Monterrey, Av. Eugenio Garza
13 Sada 2501 Sur, Tecnológico, 64849, Monterrey, Nuevo León, México.

14 ⁵ School of Engineering and Sciences, Tecnológico de Monterrey, Av. Eugenio Garza
15 Sada 2501 Sur, Tecnológico, 64849, Monterrey, Nuevo León, México.

16 ⁶ University of New South Wales, Faculty of Medicine, Sydney, Australia.

17

18

19 *Correspondence to: marion.brunck@tec.mx

20

21 **ABSTRACT**

22

23 The prevalence of obesity is rapidly increasing worldwide and its impact on future
24 generations must be assessed. We recently showed that colostrum from mothers
25 with obesity contained a significantly reduced B lymphocytes (CD19⁺) fraction.
26 Here, in a subsequent transversal cohort study of 48 mothers, we exhaustively
27 characterize the B lymphocytes subsets present in peripheral blood and colostrum
28 from obese mothers and describe a pervasive alteration of the B lymphocytes
29 compartment of human colostrum accompanied by a dysregulated antibody
30 composition. We describe significant decreases in regulatory B cells and soluble
31 IgA concentrations, combined with increases in soluble IgG and double negative 2
32 (CD19⁺, CD27⁻, IgD⁻, CD38⁻, CD24⁻, CD21⁻, CD11c⁺) B lymphocytes. These

33 alterations correlated with maternal BMI and corporal fat %. We provide evidence
34 for possibly autoimmune IgG present in obese colostrum, and for the
35 proinflammatory consequences of obese colostrum *in vitro*. Beyond the impact of
36 obesity, we evidence the selective presence of B lymphocyte subtypes in
37 colostrum and *in situ* production of IgG antibodies, which expands our current
38 understanding of the origin of colostrum IgG. As maternal milk antibodies play a
39 crucial role in regulating neonatal gut immune development, this work uncovers
40 maternal obesity as a potential risk factor for compromised breastmilk immune
41 components, calling for more research on the long-term health of lactating infants.

42

43 **KEYWORDS:** Colostrum, Obesity, B lymphocytes, IgG, IgA

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 1. INTRODUCTION

59

60 Tolerizing responses in the gut allow the establishment of the microbiota and
61 efficient food digestion, contributing to health. Disruptions in these tolerizing
62 responses cause inflammation that promote disease. For example, in ulcerative
63 colitis, immune tolerance to commensal microbes is impaired¹. This prevents the
64 expansion of a tolerizing ROR γ^+ Treg population, fueling gut inflammation that
65 primes the disease². Interestingly, ROR γ^+ Treg populations essential to the
66 establishment of the microbiota are transmitted exclusively through breastmilk and
67 persist through adulthood³. Therefore, essential immune responses in the adult gut
68 are imprinted at least in part during breastfeeding and inappropriate responses
69 prime adverse conditions later in life⁴.

70

71 Maternal obesity is a rising condition worldwide that correlates with variations in
72 multiples breastmilk components including the microbiota, Human-milk
73 oligosaccharides (HMO) and lipids⁵⁻⁸. However, reports on immune bioactives like
74 cytokines and leukocytes remain scarce⁹⁻¹². We recently evidenced a significant
75 reduction of the B lymphocytes compartment in the colostrum of mothers with
76 obesity¹³. Here, we further characterize 18 B lymphocytes subpopulations in obese
77 colostrum and describe pervasive alterations of the resolved populations, including
78 less B_{reg}-like and more of a recently described pro-inflammatory B lymphocyte
79 population, also known as double-negative 2 (DN2) B cells^{14,15}. These alterations
80 at the cellular level are accompanied by significant regulations in colostrum
81 antibodies, including less soluble IgA (slgA), and more soluble IgG (slgG).
82 Interestingly, obese colostrum slgG had increased recognition of N-
83 acetylglucosamine (GlcNAc) which is present on bacterial and fungal cell walls, but
84 also composes various human tissues, hinting toward a possible transfer of
85 autoimmunity¹⁶⁻¹⁸. Finally, we show that in contrast to colostrum from "lean"
86 mothers, obese colostrum leads to activation of human macrophages *in vitro*.
87 Overall, we describe here that maternal obesity regulates B lymphocytes subsets

88 and antibodies in human colostrum, with possible long-lasting impact on the
89 suckling neonate's health.

90

91 **2. MATERIALS AND METHODS**

92

93 **2.1 Human samples**

94 This cross-sectional study was approved by the Ethics Committee of the Hospital
95 Regional Materno Infantil, Servicios de Salud de Nuevo León, and by the IRB at
96 the School of Medicine and Health Sciences, TecSalud, in Monterrey, Mexico
97 (CarlMicrobio2018, Reg. No. DEISC-19 01 18 09). Eligible women attending the
98 hospital for delivery were recruited between September 2022 and April 2023.
99 Participation in the study was based on the following inclusion criteria: (1) maternal
100 age between 18 and 34 years, (2) over 5 prenatal visits without any adverse event
101 during pregnancy, (3) pre-pregnancy BMI >18.5 and <25, or >30, (4) term infant,
102 and (5) willingness to participate. Exclusion criteria included (1) having received
103 antibiotics anytime during the 3-month period before birth, or having received a
104 prolonged antibiotic treatment (>3 months) anytime during pregnancy, (2) having
105 received immunosuppressive doses of steroids during pregnancy, (3) history of any
106 monoclonal antibody treatment, (4) history of chronic disease (outside of obesity),
107 (5) suffering from any nutrition-related disease or dietary restrictions, (6) episodes
108 of diarrhea during the last 2 weeks of pregnancy, (7) history of surgery within 12
109 months prior to pregnancy, (8) history of antineoplastic treatment. Elimination
110 criteria included (1) having received antibiotics for >24 h post-birth, (2) newborn
111 admission to NICU, (3) any additional cause impeding sample collection. Oxytocin
112 was not used during labor. Pre-pregnancy weight was recalled, current height was
113 measured and current body fat percentage (BF%) obtained by impedance at the
114 time of recruitment. Additional variables collected or measured in this work
115 included maternal age, primiparity, infant gender, gestational age at birth, mode of
116 delivery, weight of infant at birth, volume of colostrum obtained, frequency of B
117 lymphocytes subpopulations in blood and colostrum samples, type and
118 concentrations of antibodies and frequency of antibody-producing cells in

119 colostrum. Additional details are included in the study's STROBE statement
120 (Supplementary Table 1). Participants were allocated to the "obese" (BMI>30,
121 BF%>30) or "lean" (18.5>BMI<25, BF%<22) groups according to the WHO
122 guidelines. Upon recruitment and signed informed consent, 4 ml of maternal
123 peripheral blood were drawn into K₂EDTA coated tubes (BD Vacutainer®, cat.
124 366643). The same day, after infant feeding, the nipple area of the breast was
125 gently cleaned with neutral soap and water, and 1-3 ml of colostrum were collected
126 using a manual pump. Samples were immediately stored on ice until processing
127 and all samples were processed within 2 h of collection.

128

129 **2.2 Isolation of PBMC from peripheral blood**

130 Ficoll-Paque (Fisher scientific, cat. 17-1440-03) was used to enrich PBMC from
131 peripheral blood and residual erythrocytes were lysed using Pharm Lyse Solution
132 (BD, cat. 555899), as per manufacturer's instructions. Cells were manually
133 counted using a Neubauer chamber, using 0.4% Trypan blue to discriminate dead
134 cells). Three million live PBMC were then stained for flow cytometry in a total
135 volume of 100 µl.

136

137 **2.3 Cell enrichment from colostrum**

138 Approximately 2 ml of colostrum were processed for cell enrichment prior to
139 staining for flow cytometry, as previously reported^{13,19}. Briefly, colostrum volumes
140 were recorded, and samples were centrifuged at 400 rcf for 15 min at 4°C.
141 Supernatant were stored away, and cell pellet were washed twice with PBS/1%
142 FBS/2mM EDTA. Cells were manually counted using a Neubauer chamber using
143 0.4% Trypan blue to discriminate dead cells. Two million live cells were then
144 stained for flow cytometry in a total volume of 100 µl.

145

146 **2.4 Flow cytometry**

147 The same conjugated monoclonal antibodies were used to stain both tissue types,
148 and antibody and viability stains were titrated independently for each tissue. PBMC
149 were staining with 1.38 µl of CD19-PerCP Cy5.5 (BioLegend, catalog number

150 302230), 5 μ l of CD21-PE/Dazzle™ 594 (BioLegend, catalog number 354922), 5
151 μ l of CD24-Brilliant Violet 786™ (BioLegend, catalog number 311142), 2 μ l of
152 CD27-APC (BioLegend, catalog number 302810), 2.5 μ l of CD38-Alexa Fluor® 700
153 (BioLegend, catalog number 397206), 2 μ l of IgA-VioGreen (Miltenyi Biotec,
154 catalog number 130-113-481), 3 μ l of IgG APC Cy7 (BioLegend, catalog number
155 410732), 3 μ l of IgD-VioBlue (Miltenyi Biotec, catalog number 130-123-258), and 5
156 μ l of CD11c-Brilliant Violet 605™ (BioLegend, catalog number 744436), and 1 μ l
157 of Zombie Green (BioLegend, catalog number 423111); in a final volume of 100 μ l
158 of PBS/1% FBS/2mM EDTA. As previous publications suggested we optimized
159 staining times for optimal resolution, and incubated 90 min at 4°C in the dark²⁰.
160 For colostrum cells, 2×10^6 cells were stained using a cocktail including 1.38 μ l
161 CD19-PerCP Cy5.5, 5 μ l CD21-PE/Dazzle™ 594, 5 μ l CD24-Brilliant Violet
162 786™, 2 μ l CD27-APC, 3 μ l CD38-Alexa Fluor® 700, 5 μ l IgA-VioGreen, 5 μ l IgG-
163 APC Cy7, 5 μ l IgD-VioBlue, 5 μ l IgG-APC Cy7, and 5 μ l CD11c-Brilliant Violet
164 605™; in a final volume of 100 μ l of PBS/1% FBS/2mM EDTA. After incubation,
165 samples were washed and resuspended in PBS/1% FBS/2mM EDTA for
166 immediate acquisition on a BD® FACSCelesta flow cytometer fitted with 405 nm,
167 488 nm, and 633 nm lasers and operated through the BD® FACSDiva software
168 v.8. Compensation controls were used at each acquisition using compensation
169 beads following manufacturer's recommendations, and automatic compensation
170 was performed prior to acquisition. Over 10^6 events were recorded from each
171 sample, with the FSC threshold adjusted to 50,000 or 5,000 for blood and
172 colostrum, respectively. Analysis was performed using FlowJo X 10.0.7r2. The
173 gating strategy initially optimized was based on previous reports and CD45 stained
174 samples but FMO controls were used to adjust gates for both sample types^{21,22}.
175 The gating strategy is described in Supplementary Fig. 1.

176

177 **2.5 IgM, sIgA and sIgG ELISA**

178 Flat-bottom 96-well polystyrene plates were coated with 1:5000 PBS-diluted mouse
179 anti-human monoclonal antibody for either IgM (Abcam, cat. ab200541), IgA
180 (Abcam, cat. ab7400b) or IgG (Abcam, cat. ab72528), and incubated 12 h at 4 °C.

181 After blocking, dilutions of plasma or colostrum supernatants were incubated for 2
182 h at 37 °C. For detection, anti-human IgG, IgA, and IgM coupled to HRP (Abcam,
183 cat. ab102420) were added at 1:8000 dilution and incubated for 1 h at 37 °C. Fifty
184 µl/ well of TMB (Abcam, cat. ab171523) were then incubated 2 min. The reaction
185 was stopped with 50 µl of 0.2 M H₂SO₄, and plates were read at 450 nm on a
186 spectrophotometer (Tecan's Magellan® universal reader). Quantitative standard
187 curves were obtained for each isotype using serial dilutions from recombinant
188 human IgA (Abcam, cat. ab91025), IgG (Abcam, cat. Ab91102) or IgM (Abcam,
189 cat. Ab91117).

190

191 **2.6 IgM, IgG, and IgA-secreting cells ELISPOT**

192 Briefly, 96-well plates were covered with PVDF membranes. After methanol
193 activation, membranes were coated with a 1:2500 dilution of mouse anti-human
194 monoclonal antibody recognizing IgM, IgA, or IgG (Abcam, cats. ab200541,
195 ab7400, ab72528, respectively). The plates were incubated for 12 h at 4° C, then
196 blocked for 90 min at 25 °C. Colostrum-enriched cells or blood PBMC were seeded
197 at 200,000 cells/well in RPMI 1640 with 10% FBS and 100 U/ml penicillin, 0.1
198 mg/ml streptomycin. Plates were incubated for 18 h at 37 °C and 5% of CO₂. For
199 detection, a 1:10,000 dilution of HRP-conjugated goat anti-human IgG, IgA, and
200 IgM (Abcam, cat. ab102420) was incubated 1 h at 37°C. Finally, 50 µl/well 3,3'-
201 DAB (Sigma-Aldrich, cat. D4418) were added. Membranes were then washed and
202 dried, and pictures were acquired with a Stereoscopic Microscope (Nikon, cat.
203 SMZ1500). Spots were counted using the Analyze Particles command in ImageJ
204 (Java®).

205

206 **2.7 Colostrum-mediated macrophage cytokine production**

207 To produce human macrophage-like cells, U937 cells (ATCC, CRL-1593.2) were
208 differentiated over 24 h using 10 ng/ml PMA (Sigma-Aldrich®, cat. 79346) in RPMI
209 1640, supplemented as above. After 24 h, the media was replaced without PMA
210 but including 2.5% 0.22 µm-filtered colostrum supernatant. After a further 24 h,
211 cells were washed, fresh media without colostrum was added. To quantify

212 cytokines, 5 μ L of culture supernatants were obtained every 2 h for a total of 16 h.
213 Samples were centrifuged and stored at -20 °C until quantification. Cytokines were
214 quantified using a LEGENDplex kit (BioLegend, cat. 740808) according to the
215 manufacturer's instructions. All samples were immediately read on a BD®
216 FACSCelesta flow cytometer fitted with 405 nm, 488 nm, and 633 nm lasers and
217 operated through the BD® FACSDiva software version 8. Analysis and quantitative
218 data were obtain using the FCAP Array software v 3.0 SoftFlow® LEGENDplex™
219 Cloud-based Data Analysis Software online²³.

220

221 **2. 8 Statistical Analysis**

222 Shapiro-Wilk normality tests were performed on each B lymphocyte subtype
223 dataset. Non-normal datasets were compared using Mann-Whitney or one-way
224 Kruskal-Wallis test when comparing >2 groups. Means of normally distributed data
225 were compared using Student's t test. Correlations were investigated using
226 Pearson rank or Spearman r. All these tests were performed in GraphPad Prism
227 v.8 (GraphPad Software Inc®, San Diego CA, USA). Median (IQR) were compared
228 using Independent-Samples Median test in SPSS v.26.

229

230 **3. RESULTS AND DISCUSSION**

231

232 **3.1 B lymphocytes subpopulations are selectively present in colostrum**

233 We recruited a total of 48 mothers to participate in this study. As per study design,
234 the BMI and BF% of the cohort of mothers with obesity were significantly larger
235 compared to the cohort of "lean" mothers, while no difference were observed in
236 possible confounders such as maternal age, infant gender, gestational age, or
237 delivery type between the groups (Table 1).

238 We applied an optimized 10-colour flow cytometry panel to detect 18
239 subpopulations of B lymphocytes in peripheral blood and colostrum. The gating
240 strategy was based on classical and more recent markers used to subtype
241 peripheral blood B lymphocytes (Table 2). We found a reduced fraction of the total
242 B lymphocytes population in obese colostrum compared to the lean cohort

243 (Supplementary Fig. 2), consistent with previous findings¹³. The reduction was not
244 resumed in peripheral blood, suggesting that obesity regulates this compartment
245 locally, with observed changes in colostrum.

246

247 In peripheral blood, we could detect all targeted subpopulations including rare
248 subtypes like B_{reg}-like and transitional B cells (Supplementary Fig. 3) with
249 proportions consistent with previous reports^{22,24–26}. In contrast, in colostrum
250 multiple subtypes could not be detected, notably the early stages of B cell
251 ontogeny including transitional and naïve B cells (Fig. 1A). In comparing B
252 lymphocyte subtypes between blood and colostrum, we considered relative
253 proportions (Supplementary Fig. 3), but also concentrations in original samples
254 (Fig. 1) calculated from measured sample volumes, manual cell counts and %
255 populations, to account for discrepancies in cellularity between blood and
256 colostrum (Fig. 1). Differences were consistent between population % and
257 concentrations. While early ontogeny B cells were absent from colostrum,
258 differentiated subtypes were very significantly increased in this tissue, including
259 B_{reg}-like, DN2-like and plasma-like cells that were rare in peripheral blood (Fig. 1B),
260 although definitive labelling should be based on functional assays such as cytokine
261 and antibody production. While switched memory (SwM) B cells were present in
262 similar concentrations in both colostrum and blood, unswitched memory B cells
263 (USwM) were significantly underrepresented in colostrum compared to peripheral
264 blood (Fig. 1C). Overall, the results describe pervasive, significant differences in %
265 and concentrations of B lymphocyte subtypes between blood and colostrum. This
266 may suggest a selective migration to the mammary acini and colostrum. It further
267 describes human colostrum as containing multiple subpopulations of differentiated
268 B cells, enriching the current state-of-the-art^{27,28}.

269

270 We then asked if proportions of specific B cell subpopulations in colostrum were
271 regulated with maternal obesity. In this context, we measured significantly less
272 USwM B cells without detected changes in the SwM B cells (Fig. 1C). While this
273 work is the first to report changes in breastmilk memory B cells in relation with

274 maternal obesity, others have measured increased breastmilk SwM B cells from
275 HIV-infected mothers²⁸. Increased SwM B cells were also found in mouse visceral
276 adipose tissue²⁹. IgG isotype switching follows stimulation with cytokines that are
277 increased in obesity^{29,30}. We propose that the increase in SwM B cells depletes
278 USwM, causing the significant decrease in colostrum USwM B cells. In support of
279 this, obesity peripheral blood indeed contained significantly less USwM and
280 significantly more SwM B lymphocytes (data not shown).

281

282 **3.2 Obesity colostrum harbors a dysregulated B lymphocyte repertoire,** 283 **hinting towards an inflammatory profile**

284 Looking at functional populations, we found a significantly reduced B_{reg}-like cell
285 fraction in the colostrum of mothers with obesity (Fig. 2A). The relative abundance
286 of colostrum B_{reg}-like cells negatively correlated with maternal pre-pregnancy BMI
287 and current BF%. Inflammation has been linked to decreased B_{reg}-like cells
288 functions and growth^{31,32}. Obesity is now accepted as a state of chronic
289 inflammation, which supports the physiological interpretation of the results^{33,34}. B_{reg}
290 cells limit ongoing immune reactions, restore immune homeostasis, and promote
291 tolerance to commensals of the gut microbiota, suggesting consequences of this
292 reduction for the infant's pioneering microbiota³⁵⁻³⁸. We then investigated DN2-like
293 B cells, recently described in blood in multiple inflammatory scenarios including
294 autoimmune disorders, acute infections and obesity^{22,15,39}. Consistent with the
295 inflammatory state suggested by a reduced B_{reg}-like B cell fraction, we found
296 significantly increased proportions of DN2-like cells, and these changes positively
297 correlated with pre-pregnancy BMI and current BF% (Fig. 2B). While the exact
298 origins and roles of DN2-like cells remain unclear to date, their occurrence follow a
299 proinflammatory stimulus⁴⁰⁻⁴³. Future experiments could include measuring the
300 transcription factor T-bet and IFN γ production from these cells to confirm cell
301 identity⁴⁴⁻⁴⁶. We then investigated plasma-like cells that could be producing
302 antibodies. These were increased in obesity colostrum, and as observed with DN2-
303 like B cells, colostrum plasma-like cell proportions positively correlated with pre-
304 pregnancy BMI and with current BF% (Fig. 2C). Plasma cells can differentiate

305 following IFN γ ⁴⁷ and leptin signaling⁴⁸. These soluble factors are increased in
306 obesity⁴⁹, which provides a physiological explanation for our findings.

307

308 Correlation values (r^2) for the 3 cell types were consistently higher for BF%
309 compared to BMI. Despite the historical use of BMI as an indicator of obesity, the
310 lack of precision in the composition of the measured weight is confounding. Our
311 results suggest a clearer association between increased BF% and the regulation of
312 specific B cell subtypes in human colostrum.

313

314 **3.3 Obesity modulates colostrum plasma like-cells and their antibody** 315 **secreting function**

316 Having identified a significant increase in colostrum plasma-like B cells, we
317 wondered if this population exhibited changes in their antibody production,
318 isotypes, and antigen specificity. As B cells gradually lose CD19 surface
319 expression during differentiation towards antibody-secreting cells, we measured
320 CD19 MFI within the plasma-like cell subpopulations in both groups to compare
321 their relative degree of maturity⁵⁰. We identified 3 discrete subpopulations based
322 on CD19 expression level, with a significant increase in the CD19^{low} plasma-like B
323 cell fraction in the obese cohort (Supplementary Fig. 4)⁵¹. This suggests obese
324 colostrum is enriched in plasma-like cells maturing towards antibody-secreting
325 cells, possibly driven by proinflammatory signals linked to obesity as described
326 earlier^{47,48}.

327

328 We compared isotypes of the plasma-like cells and evidenced a significantly
329 increased fraction of IgG⁺ plasma-like cells in obese colostrum, while the IgA⁺
330 fraction remained unchanged (Fig. 3A). Interestingly, intra-individual correlations of
331 IgA⁺- and IgG⁺-plasma-like cells exhibited a trend whereby obese colostrum
332 contained a switched relation of both isotypes (Fig. 3B), suggesting a
333 compensatory mechanism although more work is required to mechanistically
334 explain this. We then investigated if there were more antibody-secreting cells in
335 obese colostrum. Using an ELISPOT assay, we found a significant increase in IgG-

336 secreting cells in obese colostrum which positively correlated with maternal BMI
337 and BF% (Fig. 3C). While IgA-secreting cell concentrations remained unchanged,
338 we observed a negative correlation between their concentration, and maternal BMI
339 and BF%. These results confirm colostrum contains B cell subsets that actively
340 produce antibodies *in situ*, adding to the current understanding of breastmilk IgG
341 originating from FcN-mediated transcellular translocation⁵². We measured
342 significantly more sIgG and less sIgA concentrations in obese colostrum (Fig. 3D).
343 These changes may affect the establishment of the intestinal microbiota⁵³.
344 Dysregulations in maternal antibodies received through breastmilk also impact the
345 growth and maturation of the neonatal intestine⁵⁴. These results confirm previous
346 reports of increased local concentrations of IgG in obesity⁵⁵. We further wondered
347 if the increased IgG may be autoimmune, as accumulating evidence links obesity
348 to autoimmune disorders⁵⁶. We measured the concentration of colostrum IgG
349 specifically recognizing N-acetylglucosamine (GlcNAc), a common bacterial and
350 fungal antigen that bears similarities with circulating hyaluronic acid in obesity^{57,58}.
351 We found a very significant increase of anti-GlcNAc IgG in obese colostrum (Fig.
352 3D). The GlcNAc used as target antigen in the assay was obtained from Group A
353 *Streptococcus pyogenes* (GAS), however the incidence GAS infection is low
354 among pregnant mothers from low income countries like Mexico⁵⁹, and no
355 participant reported GAS infection during pregnancy. These results then suggest
356 autoreactive anti-GlcNAc IgG in obese colostrum, and it will be important to
357 investigate how this affects neonatal gut health.

358

359 **3.4 Obese colostrum IgG may originate from proinflammatory DN2 B** 360 **lymphocytes**

361 We then wondered what cells could produce IgG in obese colostrum. We noticed
362 DN2-like cells were almost entirely IgG⁺ (Fig. 4A), and these cells have been
363 reported to secrete IgG⁴⁰. Since obese colostrum contained significantly more IgG⁺
364 DN2-like and IgG⁺ plasma-like cells, together with more sIgG (Fig. 3C) and IgG-
365 secreting cells (Fig. 3A), we correlated IgG concentrations with these possible local
366 producers. There were clear correlations between IgG colostrum concentrations

367 and both IgG⁺ cell types in obesity but not in the lean cohort (Fig. 4B, gray and red
368 data, respectively). Looking at IgG-producing cells, the only significant correlation
369 was with the proportion of DN2-like cells, in obese colostrum only (Fig. 4C, gray
370 data), suggesting these cells participate in the production of IgG in this context. As
371 DN2 cells are mostly found in a proinflammatory setting^{15,40,60}, it will be relevant to
372 investigate the IgG subtypes produced and their consequence *in vivo*.

373

374 **3.5 Obese colostrum activates human macrophages *in vitro***

375 We finally investigated the effect of obese colostrum on human macrophages.
376 Macrophages reside in the neonatal intestine and regulate the local inflammatory
377 response during the first days of life⁶¹. Co-cultures evidenced that colostrum from
378 mothers with obesity prompted TNF- α production while colostrum from lean
379 mothers did not (Fig. 5A). Until shortly after birth, the neonatal intestine contains
380 macrophages replenished by blood monocytes due to commensal stimulation. In
381 health, these intestinal macrophages show low pro-inflammatory responses,
382 including minimal IL-6 and TNF- α expression⁶²⁻⁶⁶. Elevated TNF- α levels in the
383 neonatal intestine increases NEC pathogenesis⁶⁷. On the other hand, while IL-6
384 was significantly increased by obese colostrum stimulation, this cytokine was
385 already present in basal conditions (Fig. 5B). Overall, there was a direct induction
386 of inflammation of macrophages by obese colostrum. Further research should
387 investigate activation mechanisms and long-term consequences for neonatal
388 health.

389

390 **4. Conclusions**

391 This is the first report of obesity-mediated regulation of B lymphocytes and
392 antibodies in human colostrum. We measured notable changes in phenotypically
393 and functionally distinct B lymphocyte subpopulations, which in turn adversely
394 affect the composition of antibodies (summarized in Fig. 6). We advocate for
395 additional research to explore the underlying mechanisms in maternal gut and
396 breast tissue affected by obesity, as well as to understand the ramifications for

397 neonatal intestinal maturation, including the establishment of gut microbiota and
398 maturation of the intestine in suckling infants.

399

400 **References**

- 401 1. Shen, Z.-H. *et al.* Relationship between intestinal microbiota and ulcerative colitis:
402 Mechanisms and clinical application of probiotics and fecal microbiota transplantation. *WJG*
403 **24**, 5–14 (2018).
- 404 2. Lyu, M. *et al.* ILC3s select microbiota-specific regulatory T cells to establish tolerance in the
405 gut. *Nature* **610**, 744–751 (2022).
- 406 3. Ramanan, D. *et al.* An Immunologic Mode of Multigenerational Transmission Governs a Gut
407 Treg Setpoint. *Cell* **181**, 1276-1290.e13 (2020).
- 408 4. Brodin, P. Immune-microbe interactions early in life: A determinant of health and disease long
409 term. *Science* **376**, 945–950 (2022).
- 410 5. Gámez-Valdez, J. S. *et al.* Differential analysis of the bacterial community in colostrum samples
411 from women with gestational diabetes mellitus and obesity. *Sci Rep* **11**, 24373 (2021).
- 412 6. Azad, M. B. *et al.* 'Human Milk Oligosaccharide Concentrations Are Associated with Multiple
413 Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices.
414 *The Journal of Nutrition* **148**, 1733–1742 (2018).
- 415 7. Ellsworth, L. *et al.* Impact of maternal overweight and obesity on milk composition and infant
416 growth. *Matern Child Nutr* **16**, (2020).
- 417 8. Daniel, A. I. *et al.* Maternal BMI is positively associated with human milk fat: a systematic
418 review and meta-regression analysis. *The American Journal of Clinical Nutrition* **113**, 1009–
419 1022 (2021).

- 420 9. Collado, M. C., Laitinen, K., Salminen, S. & Isolauri, E. Maternal weight and excessive weight
421 gain during pregnancy modify the immunomodulatory potential of breast milk. *Pediatr Res* **72**,
422 77–85 (2012).
- 423 10. Fujimori, M. *et al.* Cytokine and adipokine are biofactors can act in blood and colostrum of
424 obese mothers: Cytokine and adipokine in maternal obesity. *BioFactors* **43**, 243–250 (2017).
- 425 11. Leghi, G. *et al.* The Impact of Maternal Obesity on Human Milk Macronutrient Composition: A
426 Systematic Review and Meta-Analysis. *Nutrients* **12**, 934 (2020).
- 427 12. Erliana, U. D. & Fly, A. D. The Function and Alteration of Immunological Properties in Human
428 Milk of Obese Mothers. *Nutrients* **11**, 1284 (2019).
- 429 13. Piñeiro-Salvador, R. *et al.* A cross-sectional study evidences regulations of leukocytes in the
430 colostrum of mothers with obesity. *BMC Med* **20**, 388 (2022).
- 431 14. Colonna-Romano, G. *et al.* A double-negative (IgD–CD27–) B cell population is increased in the
432 peripheral blood of elderly people. *Mechanisms of Ageing and Development* **130**, 681–690
433 (2009).
- 434 15. Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. Phenotypic and Functional Characterization
435 of Double Negative B Cells in the Blood of Individuals With Obesity. *Front. Immunol.* **12**,
436 616650 (2021).
- 437 16. Brouwer, S. *et al.* Pathogenesis, epidemiology and control of Group A Streptococcus infection.
438 *Nat Rev Microbiol* **21**, 431–447 (2023).
- 439 17. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell
440 surface receptor for hyaluronate. *Cell* **61**, 1303–1313 (1990).
- 441 18. Cywes, C. & Wessels, M. R. Group A Streptococcus tissue invasion by CD44-mediated cell
442 signalling. *Nature* **414**, 648–652 (2001).

- 443 19. Trend, S. *et al.* Leukocyte Populations in Human Preterm and Term Breast Milk Identified by
444 Multicolour Flow Cytometry. *PLoS ONE* **10**, e0135580 (2015).
- 445 20. Whyte, C. E., Tumes, D. J., Liston, A. & Burton, O. T. Do more with Less: Improving High
446 Parameter Cytometry Through Overnight Staining. *Current Protocols* **2**, (2022).
- 447 21. Cervantes-Díaz, R. *et al.* Circulating B10 regulatory cells are decreased in severe and critical
448 COVID-19. *Journal of Leukocyte Biology* **112**, 333–337 (2022).
- 449 22. Sosa-Hernández, V. A. *et al.* B Cell Subsets as Severity-Associated Signatures in COVID-19
450 Patients. *Front. Immunol.* **11**, 611004 (2020).
- 451 23. Qognit. <https://legendplex.qognit.com/user/login?next=home>.
- 452 24. Appelgren, D. *et al.* Regulatory B cells are reduced in the blood in patients with
453 granulomatosis with polyangiitis, and fail to regulate T-cell IFN- γ production. *Clin Exp Immunol*
454 **213**, 190–201 (2023).
- 455 25. Zaimoku, Y. *et al.* Deficit of circulating CD19⁺CD24^{hi}CD38^{hi} regulatory B cells in severe
456 aplastic anaemia. *Br J Haematol* **190**, 610–617 (2020).
- 457 26. Lima, J. *et al.* Characterization of B cells in healthy pregnant women from late pregnancy to
458 post-partum: a prospective observational study. *BMC Pregnancy and Childbirth* **16**, 139
459 (2016).
- 460 27. Peroni, D. G. *et al.* Colostrum-derived B and T cells as an extra-lymphoid compartment of
461 effector cell populations in humans. *The Journal of Maternal-Fetal & Neonatal Medicine* **26**,
462 137–142 (2013).
- 463 28. Tuaille, E. *et al.* Human Milk-Derived B Cells: A Highly Activated Switched Memory Cell
464 Population Primed to Secrete Antibodies. *J Immunol* **182**, 7155–7162 (2009).
- 465 29. Winer, D. A. *et al.* B cells promote insulin resistance through modulation of T cells and
466 production of pathogenic IgG antibodies. *Nat Med* **17**, 610–617 (2011).

- 467 30. O'Rourke, R. W. *et al.* Depot-specific differences in inflammatory mediators and a role for NK
468 cells and IFN-gamma in inflammation in human adipose tissue. *Int J Obes (Lond)* **33**, 978–990
469 (2009).
- 470 31. Tedder, T. F. B10 Cells: A Functionally Defined Regulatory B Cell Subset. *The Journal of*
471 *Immunology* **194**, 1395–1401 (2015).
- 472 32. Nishimura, S. *et al.* Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue
473 Inflammation. *Cell Metabolism* **18**, 759–766 (2013).
- 474 33. Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A. & Abed, Y. Obesity and inflammation: the
475 linking mechanism and the complications. *aoms* **4**, 851–863 (2017).
- 476 34. Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and
477 related disorders. *Immunity* **55**, 31–55 (2022).
- 478 35. Strom, A. *et al.* B regulatory cells are increased in hypercholesterolaemic mice and protect
479 from lesion development via IL-10. *Thromb Haemost* **114**, 835–847 (2015).
- 480 36. Mercadante, A. C. T. *et al.* Oral combined therapy with probiotics and alloantigen induces B
481 cell-dependent long-lasting specific tolerance. *J Immunol* **192**, 1928–1937 (2014).
- 482 37. Rosser, E. C. *et al.* Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-
483 Hydrocarbon Receptor Activation in Regulatory B Cells. *Cell Metabolism* **31**, 837-851.e10
484 (2020).
- 485 38. Rosser, E. C. *et al.* Regulatory B cells are induced by gut microbiota-driven interleukin-1 β and
486 interleukin-6 production. *Nat Med* **20**, 1334–1339 (2014).
- 487 39. Machann, J. *et al.* Age and gender related effects on adipose tissue compartments of subjects
488 with increased risk for type 2 diabetes: a whole body MRI / MRS study. *MAGMA* **18**, 128–137
489 (2005).

- 490 40. Jenks, S. A. *et al.* Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7
491 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* **49**, 725-
492 739.e6 (2018).
- 493 41. Woodruff, M. C. *et al.* Extrafollicular B cell responses correlate with neutralizing antibodies
494 and morbidity in COVID-19. *Nat Immunol* **21**, 1506–1516 (2020).
- 495 42. Stewart, A. *et al.* Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets
496 and Discrete Development Pathways. *Front. Immunol.* **12**, 602539 (2021).
- 497 43. Winer, D. A., Winer, S., Chng, M. H. Y., Shen, L. & Engleman, E. G. B Lymphocytes in obesity-
498 related adipose tissue inflammation and insulin resistance. *Cell. Mol. Life Sci.* **71**, 1033–1043
499 (2014).
- 500 44. Scharer, C. D. *et al.* Epigenetic programming underpins B cell dysfunction in human SLE. *Nat*
501 *Immunol* **20**, 1071–1082 (2019).
- 502 45. Stone, S. L. *et al.* T-bet transcription factor promotes antibody secreting cell differentiation by
503 limiting the inflammatory effects of IFN γ on B cells. *Immunity* **50**, 1172-1187.e7 (2019).
- 504 46. Zumaquero, E. *et al.* IFN γ induces epigenetic programming of human T-bethi B cells and
505 promotes TLR7/8 and IL-21 induced differentiation. *eLife* **8**, e41641 (2019).
- 506 47. Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic
507 autoantibody production. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 5545–5550 (2002).
- 508 48. Crouch, M., Al-Shaer, A. & Shaikh, S. R. Hormonal Dysregulation and Unbalanced Specialized
509 Pro-Resolving Mediator Biosynthesis Contribute toward Impaired B Cell Outcomes in Obesity.
510 *Mol. Nutr. Food Res.* **65**, 1900924 (2021).
- 511 49. Muskiet, F., Carrera-Bastos, P., Pruijboom, L., Lucia, A. & Furman, D. Obesity and Leptin
512 Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for
513 Severe COVID-19. *Nutrients* **14**, 1388 (2022).

- 514 50. Sanz, I. *et al.* Challenges and Opportunities for Consistent Classification of Human B Cell and
515 Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 516 51. Arumugakani, G. *et al.* Early Emergence of CD19-Negative Human Antibody-Secreting Cells at
517 the Plasmablast to Plasma Cell Transition. *The Journal of Immunology* **198**, 4618–4628 (2017).
- 518 52. Pullen, K. M. *et al.* Selective functional antibody transfer into the breastmilk after SARS-CoV-2
519 infection. *Cell Reports* **37**, 109959 (2021).
- 520 53. Pabst, O. & Slack, E. IgA and the intestinal microbiota: the importance of being specific.
521 *Mucosal Immunol* **13**, 12–21 (2020).
- 522 54. Koch, M. A. *et al.* Maternal IgG and IgA Antibodies Dampen Mucosal T Helper Cell Responses
523 in Early Life. *Cell* **165**, 827–841 (2016).
- 524 55. van Dam, A. D. *et al.* IgG is elevated in obese white adipose tissue but does not induce glucose
525 intolerance via Fcγ-receptor or complement. *Int J Obes (Lond)* **42**, 260–269 (2018).
- 526 56. Frasca, D., Diaz, A., Romero, M., Thaller, S. & Blomberg, B. B. Secretion of autoimmune
527 antibodies in the human subcutaneous adipose tissue. *PLoS One* **13**, e0197472 (2018).
- 528 57. Petrus, P. *et al.* Glutamine Links Obesity to Inflammation in Human White Adipose Tissue. *Cell*
529 *Metabolism* **31**, 375-390.e11 (2020).
- 530 58. Romo, M. *et al.* Small fragments of hyaluronan are increased in individuals with obesity and
531 contribute to low-grade inflammation through TLR-mediated activation of innate immune
532 cells. *Int J Obes* **46**, 1960–1969 (2022).
- 533 59. Sherwood, E. *et al.* Invasive group A streptococcal disease in pregnant women and young
534 children: a systematic review and meta-analysis. *The Lancet Infectious Diseases* **22**, 1076–1088
535 (2022).
- 536 60. Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell Responses in
537 Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136–1150 (2020).

- 538 61. Emami, C. N., Mittal, R., Wang, L., Ford, H. R. & Prasadarao, N. V. Role of Neutrophils and
539 Macrophages in the Pathogenesis of Necrotizing Enterocolitis Caused by Cronobacter
540 sakazakii. *Journal of Surgical Research* **172**, 18–28 (2012).
- 541 62. Shaw, T. N. *et al.* Tissue-resident macrophages in the intestine are long lived and defined by
542 Tim-4 and CD4 expression. *J Exp Med* **215**, 1507–1518 (2018).
- 543 63. Weber, B., Saurer, L., Schenk, M., Dickgreber, N. & Mueller, C. CX3CR1 defines functionally
544 distinct intestinal mononuclear phagocyte subsets which maintain their respective functions
545 during homeostatic and inflammatory conditions. *Eur J Immunol* **41**, 773–779 (2011).
- 546 64. Smith, P. D. *et al.* Intestinal macrophages lack CD14 and CD89 and consequently are down-
547 regulated for LPS- and IgA-mediated activities. *J Immunol* **167**, 2651–2656 (2001).
- 548 65. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B. L. Inflammation switches the
549 differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to
550 inflammatory dendritic cells in the colon. *J Exp Med* **209**, 139–155 (2012).
- 551 66. Smythies, L. E. *et al.* Human intestinal macrophages display profound inflammatory anergy
552 despite avid phagocytic and bacteriocidal activity. *J Clin Invest* **115**, 66–75 (2005).
- 553 67. Halpern, M. D. *et al.* Reduction of experimental necrotizing enterocolitis with anti-TNF- α .
554 *American Journal of Physiology-Gastrointestinal and Liver Physiology* **290**, G757–G764 (2006).
- 555 68. Sims, G. P. *et al.* Identification and characterization of circulating human transitional B cells.
556 *Blood* **105**, 4390–4398 (2005).
- 557 69. Suryani, S. *et al.* Differential expression of CD21 identifies developmentally and functionally
558 distinct subsets of human transitional B cells. *Blood* **115**, 519–529 (2010).
- 559 70. Palanichamy, A. *et al.* Novel Human Transitional B Cell Populations Revealed by B Cell
560 Depletion Therapy¹. *The Journal of Immunology* **182**, 5982–5993 (2009).

- 561 71. Quách, T. D. *et al.* Anergic Responses Characterize a Large Fraction of Human Autoreactive
562 Naive B Cells Expressing Low Levels of Surface IgM. *The Journal of Immunology* **186**, 4640–
563 4648 (2011).
- 564 72. Golinski, M.-L. *et al.* CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody
565 Secreting Cells in Healthy Donors. *Frontiers in Immunology* **11**, (2020).
- 566 73. Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E.-H. & Sanz, I. Extrafollicular responses in
567 humans and SLE. *Immunological Reviews* **288**, 136–148 (2019).
- 568 74. Shapiro-Shelef, M. *et al.* Blimp-1 Is Required for the Formation of Immunoglobulin Secreting
569 Plasma Cells and Pre-Plasma Memory B Cells. *Immunity* **19**, 607–620 (2003).
- 570 75. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-
571 secreting plasma cells. *Nat Rev Immunol* **15**, 160–171 (2015).
- 572 76. Bagnara, D. *et al.* A Reassessment of IgM Memory Subsets in Humans. *The Journal of*
573 *Immunology* **195**, 3716–3724 (2015).
- 574 77. Grimsholm, O. CD27 on human memory B cells—more than just a surface marker. *Clinical and*
575 *Experimental Immunology* **213**, 164–172 (2023).
- 576 78. Saunders, S. P., Ma, E. G. M., Aranda, C. J. & Curotto de Lafaille, M. A. Non-classical B Cell
577 Memory of Allergic IgE Responses. *Frontiers in Immunology* **10**, (2019).
- 578 79. Sutton, H. J. *et al.* Atypical B cells are part of an alternative lineage of B cells that participates
579 in responses to vaccination and infection in humans. *Cell Reports* **34**, 108684 (2021).
- 580 80. Wang, S. *et al.* IL-21 drives expansion and plasma cell differentiation of autoreactive
581 CD11chiT-bet+ B cells in SLE. *Nat Commun* **9**, 1758 (2018).
- 582 81. CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are
583 Functionally Impaired in Systemic Lupus Erythematosus Patients: Immunity.
584 [https://www.cell.com/immunity/fulltext/S1074-7613\(09\)00547-](https://www.cell.com/immunity/fulltext/S1074-7613(09)00547-)

585 0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS10747613090

586 05470%3Fshowall%3Dtrue.

587 82. Mauri, C. & Menon, M. Human regulatory B cells in health and disease: therapeutic potential.

588 *J Clin Invest* **127**, 772–779 (2017).

589

590 **AUTHOR CONTRIBUTIONS**

591 All authors approved the final version of the manuscript. ESS designed and
592 performed experiments, analyzed data and wrote, edited, and reviewed the
593 manuscript. DBR performed experiments, analyzed data and reviewed the
594 manuscript. MRAG, VJLD and CNLV, designed experiments, enrolled participants,
595 collected samples, edited, and reviewed the manuscript. MEGB designed the
596 study, analyzed data, wrote, edited, and reviewed the manuscript.

597

598 **DECLARATION OF COMPETING INTEREST**

599 The authors declare no conflict of interest.

600

601 **FUNDING**

602 This research was supported by the Institute for Obesity Research and the Centro
603 de Biotecnología FEMSA of Tecnológico de Monterrey, and sponsored by
604 StrainBiotech SAPI de CV.

605

606 **DATA AVAILABILITY**

607 All .fcs3 files obtained as part of this work will be made freely available on
608 FlowRepository upon paper acceptance (in process)

609

610 **ACKNOWLEDGEMENTS**

611 We acknowledge institutional support in all administrative processes involved with
612 a clinical study. We are deeply grateful to participating families.

613

614 Table 1: Participants characteristics

Variable	Group				P value
	Lean, n = 23		Obese, n = 25		
Maternal age (years) ^a	21	(20 - 24)	23.5	(20 -27.5)	0.099
BMI (kg/m ²) ^a	21.4	(18.7 - 24.1)	30.3	(30.0 - 31.9)	<0.0001
Body fat percentage (%) ^a	20	(15 - 22)	39.1	(34 - 42)	<0.0001
Gestational age (weeks) ^a	38	(37 - 39)	38	(37 - 39)	0.690
Primiparity ^a	2	(1 - 3)	3	(1.75 - 4)	0.104
Vaginal delivery ^b	23	(100)	24	(92.3)	0.491
Newborn female gender ^b	9	(39.1)	15	(60)	0.156
Newborn male gender ^b	14	(60.9)	10	(40)	
Birth weight (g) ^a	3070	(2700 - 3290)	3000	(2742 - 3255)	0.411
Birth height (cm) ^a	49	(47 - 50)	49	(47 - 50)	0.832

615

616 Notes: BMI = Body Mass Index; a = Values expressed as median (IQR), statistical
 617 analysis with Independent-Samples Median test, b = Values expresses as
 618 frequency (%), statistical analysis with Fisher's exact test.

619

620 Table 2: Flow cytometry-based identification of B lymphocyte subtypes

B cell subpopulation (acronym)	Surface markers phenotype	References
Total B cells (B cells)	CD19 ⁺	27
Transitional B cells type 1 (T1)	CD19 ⁺ , CD27 ⁻ , CD38 ^{hi} , CD24 ^{hi} , CD21 ^{neg/low}	68,69
Transitional B cells type 2 (T2)	CD19 ⁺ , CD27 ⁻ , CD38 ^{hi} , CD24 ^{hi} , CD21 ⁺	69,70
Resting naïve B cells (resN)	CD19 ⁺ , CD27 ⁻ , IgD ⁺ , CD38 ⁺ , CD24 ⁻ , CD11c ⁻	71,72

Active naïve B cells (actN)	CD19 ⁺ , CD27 ⁻ , IgD ⁺ , CD38 ⁺ , CD24 ⁻ , CD11c ⁺	72,73
Total plasma-like cells (Plasma-like cells)	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi}	74,75
Plasma-like cells expressing IgA (IgA⁺ plasma-like cells)	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi} , IgA ⁺	
Plasma-like cells expressing IgG (IgG⁺ plasma-like cells)	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi} , IgG ⁺	
Unswitched memory B cells (USwM)	CD19 ⁺ , CD27 ⁺ , IgD ⁺	76,77
IgG switched memory (IgG⁺ SwM)	CD19 ⁺ , CD27 ⁺ , IgD ⁻ , IgG ⁺	
IgA switched memory (IgA⁺ SwM)	CD19 ⁺ , CD27 ⁺ , IgD ⁻ , IgA ⁺	
Unswitched non-classical memory (M CD27⁻ IgD⁺)	CD19 ⁺ , CD38 ^{neg/low} , CD24 ⁺ , CD27 ⁻ , IgD ⁺	78,79
Switched non-classical memory or (M CD27⁻ IgD⁻)	CD19 ⁺ , CD38 ^{neg/low} , CD24 ⁺ , CD27 ⁻ , IgD ⁻	
Double negative B cell subtype 1 (DN1-like)	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ^{-/+} , CD24 ⁻ , CD21 ⁺ , CD11c ⁻	40,80
Double negative B cell subtype 2 (DN2-like)	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ⁻ , CD24 ⁻ , CD21 ⁻ , CD11c ⁺	
Double negative B cell subtype 3 (DN3-like)	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ^{-/+} , CD24 ⁻ , CD21 ⁻ , CD11c ⁻	
Double negative B cell subtype 4 (DN4-like)	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ⁻ , CD24 ⁻ , CD21 ⁺ , CD11c ⁺	
B reg-like cells (B_{reg}-like cells)	CD19 ⁺ , CD38 ⁺ , CD24 ⁺	81,82

621

622 **FIGURE LEGENDS**

623

624 **Fig. 1: Human colostrum and peripheral blood are differentially enriched in**
625 **multiple B lymphocyte subtypes. a)** Concentrations of transitional and naïve B
626 cells in peripheral blood and colostrum. **b)** Concentrations of B_{reg}-like, DN2-like and
627 plasma-like cells in peripheral blood and colostrum. **c)** Concentrations of USwM
628 and SwM in blood and colostrum (above) and subsampling comparing samples
629 from mothers with BMI<25 ("lean") and mothers with BMI>30 ("obese") (below).
630 Statistical analysis was performed using Mann-Whitney U tests, comparing B cell
631 subsets concentrations (live cells/ml or original blood or colostrum) from mothers
632 with obesity (n=25) or with a lean BMI (n=23). *p < 0.05, **p< 0.01, ***p < 0.001
633 and ****p < 0.0001.

634

635 **Fig. 2: Maternal BMI and BF% correlates with the frequency of Breg-like,**
636 **double-negative (DN2) and plasma-like cells in colostrum.** Comparisons of **a)**
637 B_{reg}-like, **b)** DN2-like and **c)** plasma-like cell % in colostrum from lean and obese
638 cohorts (left of the 3 panels), and correlations with between pre-pregnancy BMI
639 values (middle) and BF% (right). Doted lines represent SE. Mann-Whitney U tests
640 were used to compare B cell subsets in colostrum from both cohorts. Pearson
641 correlations were used to investigate the relationships between B cell subsets %
642 and BMI or BF%. **p < 0.01 and ****p < 0.0001.

643

644 **Fig. 3: IgG production is increased in colostrum from mothers with obesity.**
645 **a)** Relative contribution of IgA⁺ and IgG⁺ plasma-like cells between cohorts (mean
646 ± SD). Comparisons performed using Mann-Whitney U test **p<0.01. **b)** Intra-
647 individual correlation analysis of IgA⁺ and IgG⁺ colostrum plasma-like cells in both
648 groups. Spearman tests compared Z-Scores of IgA⁺ and IgG⁺ plasma-like cells
649 proportions. **c)** Comparison of IgG and IgA-secreting colostrum cells in both
650 cohorts (left), and Pearson correlations with maternal BMI (middle) and BF%
651 (right). **d)** Concentration of total IgG (mg/ml) and GlcNAc-specific IgG (ng/ml)
652 (above) and total IgA (mg/ml) in both groups (individual data, with mean ± SD).
653 Comparisons performed through Mann-Whitney U test *p < 0.05, **p<0.01, ****p <
654 0.0001.

655

656 **Fig. 4: IgG⁺-DN2 cells and IgG⁺-plasma like cells contribute to local IgG**
657 **production in obesity. a)** Representative colostrum DN2-like B cells plot showing
658 IgA or IgG expression. **b)** Correlations between IgG⁺ plasma-like cells and DN2-
659 like cell proportions with IgG concentrations in lean (red) and obese (gray) cohorts.
660 **c)** Correlations between IgG⁺ plasma-like cells and DN2-like cell proportions with
661 concentrations of IgG-secreting cells in lean (red) and obese (gray) cohorts.
662 Trends were compared by Spearman rank.

663

664 **Fig. 5: Obese colostrum prompts cytokines production by human**
665 **macrophages.** Supernatant concentrations of **a)** TNF- α and **b)** IL-6 produced over
666 a 16h period by human macrophages (black), human macrophages incubated for
667 24 h with filtered colostrum supernatant from the lean cohort (gray) or obese cohort
668 (red). Each timepoint represents the mean of three biological replicates \pm SD.
669 Comparisons with two-way ANOVA and Turkey's post-hoc test. *p < 0.05,
670 **p<0.01, ***p<0.001 and ****p < 0.0001.

671

672 **Fig. 6: Overview of obesity-related alterations in B lymphocyte subtypes in**
673 **maternal peripheral blood and colostrum.** Transitional B cells (1) differentiate
674 into B_{reg} cells (2) and migrate from the blood into the lactating duct (2a).
675 Transitional B cells (1) also migrate to secondary tissues. There, transitional B cells
676 differentiate into naïve B cells (3) and enter germinal centers (3a) or are activated
677 through the extrafollicular pathway to differentiate into DN2-like B cells (4). These
678 (4) could migrate to multiple tissues, including the lactating mammary gland and
679 colostrum (4a), where they are increased in obesity. Here we provide evidence that
680 DN2-like B cells could differentiate into IgG⁺ plasma-like cells (6a) and IgG-
681 secreting cells (7a) to increase IgG produced in obesity (8). In the germinal center,
682 naïve B cells (3), after germinal center reaction (3a) and can differentiate into two
683 subpopulations: (5) memory B cells or (6) plasma-like cells. Memory B cells
684 migrate through blood to mammary acini and colostrum (5a). We have shown that
685 in obesity, colostrum USwM cells are decreased. Finally, colostrum IgG-secreting

686 cells and sIgG increase in obesity (7a) while colostrum IgA-secreting cells and sIgA
687 are reduced (8). Created with BioRender.com

688

689 **Supplementary Fig. 1: Gating strategy used for manual gating of B cells**
690 **subsets in colostrum.** Transitional B cells in brown, naïve B cells in yellow,
691 regulatory B cells in green, memory B cells in orange, plasma-like cells in red, and
692 double-negative B cell subsets (DN1, DN2, DN3 and DN4) in blue. Dot plots are
693 represented in Contour plots, at least at 5% of level and included outliers in FlowJo
694 X® version Software, BD Biosciences.

695

696 **Supplementary Fig. 2: CD19⁺ B cells are decreased in the colostrum from**
697 **mothers with obesity a)** Total CD19⁺ B cells in blood and in colostrum from both
698 cohorts. Groups compared using Mann-Whitney U test. ***p < 0.001.

699

700 **Supplementary Fig. 3: Human colostrum contains percentages of**
701 **subpopulations of differentiated B cells enriching in comparison with blood.**
702 **a)** Scatter plots comparing transitional and naïve B cells in blood and colostrum. **b)**
703 Scatter plots comparing regulatory B cells (Breg-like), double negative 2 (DN2-like)
704 and plasma-like cells in blood and in colostrum. **c)** Scatter plots comparing
705 unswitched memory (USwM) and switched memory B cells (SwM) in blood and
706 colostrum (above). Scatter plots comparing USwM and SwM in colostrum from
707 lean and mothers with obesity (below). Statistical analysis was performed using the
708 Mann-Whitney U test, comparing B cell subsets percentages in blood from mothers
709 with obesity (n=25) against lean subjects as control (n=23). *p < 0.05, **p < 0.01,
710 ***p < 0.001 and ****p < 0.0001.

711

712 **Supplementary Fig. 4. Obesity induces differentiation of plasma-like cells on**
713 **CD19 low expression group. a,b)** Examples of histograms from plasma-like cells
714 analyzed in function of CD19 expression, showing negative CD19 population (left)
715 and positive CD19 expression groups (right), from colostrum of lean and mothers.
716 **c)** Column bar graph comparing plasma-like cells in function of percentage of (% of

717 CD19⁺) low (no pattern), median (square pattern), and high (line pattern) CD19
718 expression groups. Bars indicate the mean \pm SD. Statistical analysis was
719 performed using the Kruskal Wallis test for multiple comparisons (Lean n=23 and
720 obesity n=25) assay. ***p<0.001.

Fig. 1







Fig. 2















Fig. 3**A****B****C****D**

Fig. 4

A



B



C







Fig. 5

A




B




- Unstimulated
- ▲ Co-incubation with lean colostrum supernatant
- ▼ Co-incubation with obese colostrum supernatant



Fig. 6






Supplementary Fig. 1



Supplementary Fig. 2




Supplementary Fig. 3




Supplementary Fig. 4

A



B



C

